AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +75

AbbVie (NYSE:ABBV) Stock Price Expected to Rise, Canaccord Genuity ...

📈 Canaccord Genuity raised its price target on AbbVie from $273.00 to $282.00, citing a 'buy' rating and potential upside of 9.81%.

📊 Bank of America increased its target to $276.00 with a 'buy' rating, while JPMorgan boosted its objective to $280.00 with an 'overweight' rating.

💰 BMO Capital Markets raised its price target to $300.00 and assigned an 'outperform' rating on July 13th.

📉 HSBC reaffirmed a 'buy' rating with a $300.00 price target, contributing to a consensus 'Moderate Buy' rating across analysts.

💵 AbbVie reported Q2 earnings of $2.65 per share, beating the consensus estimate of $2.59 by $0.06.

📈 Revenue reached $15 billion for the quarter, surpassing the $14.72 billion consensus and growing 12.4% year-over-year.

🔮 Analysts project full-year earnings of $14.18 per share based on current market data and company performance trends.

🏦 Institutional ownership stands at 70.23%, with hedge funds like Imprint Wealth LLC increasing positions by over 56% in Q4.

🧬 The company focuses on complex chronic conditions across immunology, oncology, neuroscience, virology, and women's health therapeutic areas.

📍 AbbVie is headquartered in North Chicago, Illinois, operating as a global research-driven biopharmaceutical entity spun off from Abbott Laboratories.

Bullish Signals
  • Canaccord Genuity raised its price target to $282.00, indicating a 9.81% upside potential from current levels.
  • Bank of America increased its price target to $276.00 and maintained a 'buy' rating on the stock.
  • JPMorgan Chase boosted its price objective to $280.00 with an 'overweight' rating, signaling strong analyst confidence.
  • BMO Capital Markets raised its target to $300.00 and assigned an 'outperform' rating, reflecting positive outlook.
  • AbbVie beat quarterly earnings expectations with $2.65 EPS versus the consensus of $2.59.
  • Revenue of $15 billion exceeded analyst estimates of $14.72 billion, demonstrating strong top-line growth.
  • The company achieved a 12.4% year-over-year revenue increase, highlighting robust business expansion.
  • Institutional investors increased holdings in Q4, with Imprint Wealth LLC boosting its stake by 56.2% and Legacy Wealth Managment LLC ID growing its position by 115.9%.
Full Analysis
AbbVie (NYSE: ABBV) stock received a price target boost from Canaccord Genuity, which raised its objective from $273.00 to $282.00 while maintaining a 'buy' rating, suggesting potential upside of 9.81% from current levels. This follows a series of positive analyst actions in July and early August, including Bank of America raising its target to $276.00 with a 'buy' rating on July 10th, JPMorgan increasing its objective to $280.00 with an 'overweight' rating on July 9th, and BMO Capital Markets lifting its target to $300.00 with an 'outperform' rating on July 13th. The company recently reported strong quarterly financial results released on April 29th, beating consensus estimates for both earnings per share and revenue. AbbVie posted $2.65 in EPS compared to the expected $2.59, driven by revenue of $15 billion which exceeded the $14.72 billion estimate. The quarter saw a 12.4% year-over-year revenue increase, with analysts projecting full-year earnings of $14.18 per share. Institutional ownership remains significant at 70.23%, with several hedge funds and wealth management firms increasing their stakes in the fourth quarter. Notable activity includes Imprint Wealth LLC boosting its position by 56.2% to own 125 shares, Legacy Wealth Managment LLC ID growing its holding by 115.9% to 136 shares, and new positions taken by Litman Gregory Wealth Management LLC and IFC & Insurance Marketing Inc., indicating continued institutional interest in the biopharmaceutical giant.